Related Experiment Videos
Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice
M Marien1, M Briley, F Colpaert
1Division Neurobiologie I, Centre de Recherche Pierre Fabre, Castres, France.
Abstract:
Injection of C57Bl/6 mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 4 x 10 mg/kg i.p. over 8 h) resulted in a partial (40%) striatal dopamine depletion at 7 days post-drug. Pretreatment with the selective noradrenergic neurotoxin N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine (DSP-4; 40 mg/kg i.p.), while having no effect per se on striatal dopamine levels, exacerbated the MPTP-induced dopamine deficit to 60%. Results support the hypothesis that damage to the locus coeruleus-noradrenergic system, by removing a facilitatory influence on the nigrostriatal dopamine system, interferes with the ability of the nigrostriatal pathway to compensate for or recover from injury.
Insights
Damage to the noradrenergic system exacerbates MPTP-induced dopamine depletion in mice. This suggests the noradrenergic system normally aids the nigrostriatal pathway
Area of Science:
- Neuroscience
- Neuropharmacology
- Neurotoxicology
Background:
- The nigrostriatal dopamine pathway is crucial for motor control.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that selectively damages dopaminergic neurons in this pathway, modeling Parkinson's disease.
- The role of the noradrenergic system in modulating dopamine system integrity is not fully understood.
Purpose of the Study:
- To investigate the interaction between the noradrenergic system and MPTP-induced dopaminergic neurotoxicity.
- To determine if damage to the noradrenergic system affects the nigrostriatal pathway's response to MPTP.
Main Methods:
- C57Bl/6 mice were injected with MPTP to induce dopamine depletion.
- Mice were pretreated with N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine (DSP-4), a selective noradrenergic neurotoxin.
- Striatal dopamine levels were measured 7 days post-MPTP administration.
Main Results:
- MPTP alone caused a 40% depletion of striatal dopamine.
- DSP-4 pretreatment exacerbated MPTP-induced dopamine depletion to 60%.
- DSP-4 alone did not affect striatal dopamine levels.
Conclusions:
- Noradrenergic system integrity is important for the nigrostriatal dopamine pathway's resilience to MPTP toxicity.
- Noradrenergic pathways may provide a facilitatory influence that aids in the compensation or recovery of the nigrostriatal system following injury.
- Targeting the noradrenergic system could be a potential therapeutic strategy for neurodegenerative conditions affecting dopamine pathways.